- - -
IPPF/Tommy Trenchard

Resources

Latest resources from across the federation and our partners

Spotlight

A selection of resources from across the Federation

HIV
Resource

HIV Theory of Change

Our HIV Theory of Change is to clarify the goals and vision of IPPF’s HIV programme and to articulate the different pathways and strategies IPPF uses to contribute towards its HIV goals and vision.
Two young people smiling
Resource

| 21 September 2020

It's All One Curriculum

Researchers have identified gender inequality as a key factor driving the AIDS pandemic. Policymakers have called for sexuality and HIV education that emphasizes gender equality and human rights. Educators want to teach young people the critical thinking skills needed to build compassionate and just societies. It's All One Curriculum responds to these calls.

Two young people smiling
Resource

| 21 September 2020

It's All One Curriculum

Researchers have identified gender inequality as a key factor driving the AIDS pandemic. Policymakers have called for sexuality and HIV education that emphasizes gender equality and human rights. Educators want to teach young people the critical thinking skills needed to build compassionate and just societies. It's All One Curriculum responds to these calls.

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Floods in Belkuchi, Bangladesh
Resource

| 03 April 2019

Improving the quality and availability of post-abortion care in a humanitarian crisis

The world is facing stronger and longer natural disasters, protracted complex emergencies, conflicts and epidemics. These humanitarian crises can expose weakness in health systems, with particularly serious consequences for women and girls in need of reproductive health care. To improve the quality and availability of post‑abortion care during a flood, the University of Leicester and International Planned Parenthood Federation South Asia Region (IPPF-SAR), in collaboration with the Government of Bangladesh, developed and measured the impact of an integrated intervention package, called RHCC. First tested in a flood-prone area of Bangladesh, this novel approach includes: i) Pre-positioning medicines and supplies, using the UNFPA’s Inter-Agency Reproductive Health Kit 8; ii) Capacity building of service providers; and iii) Community awareness raising. Supported by IPPF's Innovation Programme, the project aligns with IPPF’s commitment to ensuring that crisis-affected populations receive timely, quality, life-saving, gender-responsive and inclusive sexual and reproductive health services.  

Floods in Belkuchi, Bangladesh
Resource

| 03 April 2019

Improving the quality and availability of post-abortion care in a humanitarian crisis

The world is facing stronger and longer natural disasters, protracted complex emergencies, conflicts and epidemics. These humanitarian crises can expose weakness in health systems, with particularly serious consequences for women and girls in need of reproductive health care. To improve the quality and availability of post‑abortion care during a flood, the University of Leicester and International Planned Parenthood Federation South Asia Region (IPPF-SAR), in collaboration with the Government of Bangladesh, developed and measured the impact of an integrated intervention package, called RHCC. First tested in a flood-prone area of Bangladesh, this novel approach includes: i) Pre-positioning medicines and supplies, using the UNFPA’s Inter-Agency Reproductive Health Kit 8; ii) Capacity building of service providers; and iii) Community awareness raising. Supported by IPPF's Innovation Programme, the project aligns with IPPF’s commitment to ensuring that crisis-affected populations receive timely, quality, life-saving, gender-responsive and inclusive sexual and reproductive health services.  

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

IMAP statement SRH in Humanitarian settings
Resource

| 17 September 2018

IMAP statement on sexual and reproductive health in Humanitarian settings

Today, unprecedented numbers of people are living in a state of crisis or emergency. In 2018, it is estimated that 135.7 million people are in need of humanitarian assistance, with conflict and natural disasters predicted to be the biggest drivers. Of those in need, approximately one-quarter is estimated to be women and girls of reproductive age (aged 15–49) and approximately 5 million will be pregnant. Globally, 60% of preventable maternal deaths take place in settings of conflict, fragility, displacement and natural disasters.

IMAP statement SRH in Humanitarian settings
Resource

| 17 September 2018

IMAP statement on sexual and reproductive health in Humanitarian settings

Today, unprecedented numbers of people are living in a state of crisis or emergency. In 2018, it is estimated that 135.7 million people are in need of humanitarian assistance, with conflict and natural disasters predicted to be the biggest drivers. Of those in need, approximately one-quarter is estimated to be women and girls of reproductive age (aged 15–49) and approximately 5 million will be pregnant. Globally, 60% of preventable maternal deaths take place in settings of conflict, fragility, displacement and natural disasters.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

Two young people smiling
Resource

| 21 September 2020

It's All One Curriculum

Researchers have identified gender inequality as a key factor driving the AIDS pandemic. Policymakers have called for sexuality and HIV education that emphasizes gender equality and human rights. Educators want to teach young people the critical thinking skills needed to build compassionate and just societies. It's All One Curriculum responds to these calls.

Two young people smiling
Resource

| 21 September 2020

It's All One Curriculum

Researchers have identified gender inequality as a key factor driving the AIDS pandemic. Policymakers have called for sexuality and HIV education that emphasizes gender equality and human rights. Educators want to teach young people the critical thinking skills needed to build compassionate and just societies. It's All One Curriculum responds to these calls.

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

IMAP Statement ECHO Trial
Resource

| 09 July 2019

IMAP statement on the ECHO trial

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Floods in Belkuchi, Bangladesh
Resource

| 03 April 2019

Improving the quality and availability of post-abortion care in a humanitarian crisis

The world is facing stronger and longer natural disasters, protracted complex emergencies, conflicts and epidemics. These humanitarian crises can expose weakness in health systems, with particularly serious consequences for women and girls in need of reproductive health care. To improve the quality and availability of post‑abortion care during a flood, the University of Leicester and International Planned Parenthood Federation South Asia Region (IPPF-SAR), in collaboration with the Government of Bangladesh, developed and measured the impact of an integrated intervention package, called RHCC. First tested in a flood-prone area of Bangladesh, this novel approach includes: i) Pre-positioning medicines and supplies, using the UNFPA’s Inter-Agency Reproductive Health Kit 8; ii) Capacity building of service providers; and iii) Community awareness raising. Supported by IPPF's Innovation Programme, the project aligns with IPPF’s commitment to ensuring that crisis-affected populations receive timely, quality, life-saving, gender-responsive and inclusive sexual and reproductive health services.  

Floods in Belkuchi, Bangladesh
Resource

| 03 April 2019

Improving the quality and availability of post-abortion care in a humanitarian crisis

The world is facing stronger and longer natural disasters, protracted complex emergencies, conflicts and epidemics. These humanitarian crises can expose weakness in health systems, with particularly serious consequences for women and girls in need of reproductive health care. To improve the quality and availability of post‑abortion care during a flood, the University of Leicester and International Planned Parenthood Federation South Asia Region (IPPF-SAR), in collaboration with the Government of Bangladesh, developed and measured the impact of an integrated intervention package, called RHCC. First tested in a flood-prone area of Bangladesh, this novel approach includes: i) Pre-positioning medicines and supplies, using the UNFPA’s Inter-Agency Reproductive Health Kit 8; ii) Capacity building of service providers; and iii) Community awareness raising. Supported by IPPF's Innovation Programme, the project aligns with IPPF’s commitment to ensuring that crisis-affected populations receive timely, quality, life-saving, gender-responsive and inclusive sexual and reproductive health services.  

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

Leaving no one behind
Resource

| 04 December 2018

Leaving no one behind: Universal health coverage and sexual and reproductive health and rights

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

IMAP statement SRH in Humanitarian settings
Resource

| 17 September 2018

IMAP statement on sexual and reproductive health in Humanitarian settings

Today, unprecedented numbers of people are living in a state of crisis or emergency. In 2018, it is estimated that 135.7 million people are in need of humanitarian assistance, with conflict and natural disasters predicted to be the biggest drivers. Of those in need, approximately one-quarter is estimated to be women and girls of reproductive age (aged 15–49) and approximately 5 million will be pregnant. Globally, 60% of preventable maternal deaths take place in settings of conflict, fragility, displacement and natural disasters.

IMAP statement SRH in Humanitarian settings
Resource

| 17 September 2018

IMAP statement on sexual and reproductive health in Humanitarian settings

Today, unprecedented numbers of people are living in a state of crisis or emergency. In 2018, it is estimated that 135.7 million people are in need of humanitarian assistance, with conflict and natural disasters predicted to be the biggest drivers. Of those in need, approximately one-quarter is estimated to be women and girls of reproductive age (aged 15–49) and approximately 5 million will be pregnant. Globally, 60% of preventable maternal deaths take place in settings of conflict, fragility, displacement and natural disasters.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.

dolutegravir (DTG)
Resource

| 02 August 2018

Technical brief: Dolutegravir for women living with HIV of reproductive age

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.